Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: opty / Re: FutTheWuk / Re: Just curious why nobody thought the following was

I think your math is wrong. PDS ended the quarter on Nov. 30 with $325,442 in its cash & equivalents line item. That's AFTER PDS (not PTSC & TPL each) took in $1.409M in licensing revenue for the quarter, and spent $2M in expenses. So PDS was running a negative for the quarter, and had negative equity for each of the 2 members, so no cash was distributed to PTSC or TPL because there was no positive cash flow for the quarter. I think all the machinations you mention are already reflected in the 10q number.

The filing states that as of Jan 13 (the day before the filing) PDS had a "cash and equivalents" line item of $7,007,897. That's an increase to that line item of $6,682,475. Presumably, that was cash influx to PDS that built up the Nov. 30 reported number. Not sure what accounting rules would dictate, but since PDS already had reported $100K in prepaid expenses in the 10q, I'll assume that carried them for the last 45 days, and that they haven't deducted any expenses from that number since they only mention the cash and equivalents number, and not also, expenses incurred over that same time period from 11/30 to 1/13.

I suppose it's possible, if PDS spent $2.9M over the last 6 months, that they could have spent $725K over the last 1 1/2 months, so perhaps that $6.68M was really $7.4M that was added in, but I don't see a scenario that gets us to $11.5M to $12M based on what we know.

Still, if they took in $6.68M for ONE license, it would be the most significant signing since the Bosch quarter, which can give a glimpse as to how much TPL may have been diverting from previous licenses, depending on who that one signer was. If it's from 10 licenses, not so significant, other than to reflect people are signing up. We won't know the answer likely until the next 10q, unless the company will tell us in the SHM whether the funds came from licensing, and how many licenses it reflects.

Share
New Message
Please login to post a reply